These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8994703)

  • 1. Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma.
    Jaeger HJ; Mehring UM; Castañeda F; Hasse F; Blumhardt G; Loehlein D; Mathias KD
    Cardiovasc Intervent Radiol; 1996; 19(6):388-96. PubMed ID: 8994703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
    Takayasu K; Arii S; Ikai I; Kudo M; Matsuyama Y; Kojiro M; Makuuchi M;
    AJR Am J Roentgenol; 2010 Mar; 194(3):830-7. PubMed ID: 20173167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization.
    Sumie S; Yamashita F; Ando E; Tanaka M; Yano Y; Fukumori K; Sata M
    AJR Am J Roentgenol; 2003 Nov; 181(5):1327-34. PubMed ID: 14573429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma.
    He M; Li Q; Shen J; Tan G; Li Q; Lai J; Wei W; Zhang Y; Zou R; Chen M; Guo R; Shi M
    Cancer Med; 2019 Aug; 8(9):4200-4213. PubMed ID: 31207163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
    Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.
    Mabed M; Esmaeel M; El-Khodary T; Awad M; Amer T
    Eur J Cancer Care (Engl); 2009 Sep; 18(5):492-9. PubMed ID: 19453695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a safety index of transarterial chemoembolization for hepatocellular carcinoma to prevent acute liver damage.
    Hwang JI; Chow WK; Hung SW; Li TC; Cheng YP; Ho YJ; Lin CC
    Anticancer Res; 2005; 25(3c):2551-4. PubMed ID: 16080491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of liver resection with sequential transarterial chemoembolization in stage pT3 or pT4 hepatocellular carcinoma].
    Hasse F; Mehring UM; Castaneda F; Jäger H; Mathias KD; Löhlein D
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():208-10. PubMed ID: 9101833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
    Seki A; Hori S
    Cardiovasc Intervent Radiol; 2012 Jun; 35(3):555-62. PubMed ID: 21562932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival.
    Kirchhoff TD; Bleck JS; Dettmer A; Chavan A; Rosenthal H; Merkesdal S; Frericks B; Zender L; Malek NP; Greten TF; Kubicka S; Manns MP; Galanski M
    Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):259-66. PubMed ID: 17548248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The results of the chemoembolization of advanced hepatocellular carcinomas. The effect on the survival times, morphological findings and tumor markers].
    Wickenhöfer R; Hasan I; Schüller H; Reiser M; Hartlapp JH
    Rofo; 1992 Apr; 156(4):328-32. PubMed ID: 1373966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion.
    Kamada K; Nakanishi T; Kitamoto M; Aikata H; Kawakami Y; Ito K; Asahara T; Kajiyama G
    J Vasc Interv Radiol; 2001 Jul; 12(7):847-54. PubMed ID: 11435541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial.
    Aramaki O; Takayama T; Moriguchi M; Sakamoto H; Yodono H; Kokudo N; Yamanaka N; Kawasaki S; Sasaki Y; Kubota K; Otsuji E; Tanaka S; Matsuyama Y; Fujii M;
    Eur J Cancer; 2021 Nov; 157():373-382. PubMed ID: 34563992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oily chemoembolization combined with degradable starch microspheres for HCC with cirrhosis.
    Murata S; Tajima H; Ichikawa K; Onozawa S; Wang J; Kumita S; Nomura K
    Hepatogastroenterology; 2008; 55(84):1041-6. PubMed ID: 18705325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma.
    Chen MS; Li JQ; Zhang YQ; Lu LX; Zhang WZ; Yuan YF; Guo YP; Lin XJ; Li GH
    World J Gastroenterol; 2002 Feb; 8(1):74-8. PubMed ID: 11833075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma.
    Kamada K; Kitamoto M; Aikata H; Kawakami Y; Kono H; Imamura M; Nakanishi T; Chayama K
    Am J Surg; 2002 Sep; 184(3):284-90. PubMed ID: 12354601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.